Obesity treatment involves personalized medical care to reduce excess body fat, improve health and support long-term weight management. Depending on a person’s needs, treatment may include nutrition and physical activity programs, behavioral support, prescription medication or metabolic and bariatric surgery.
Obesity is a chronic, often relapsing disease influenced by genetics, hormones, biology, medications, environmental factors and other circumstances. Effective treatment goes beyond simply eating less or exercising more.
New medicines such as semaglutide and tirzepatide have expanded treatment options, but no medication or procedure is suitable for everyone.
Through Tabeebo, patients can explore healthcare professionals and clinics, compare available services and contact providers to discuss individualized treatment options.
What Is Obesity and How Is It Diagnosed?
Obesity involves excess body fat that can adversely affect health.
The body mass index (BMI) is a commonly used screening measure calculated by dividing weight in kilograms by height in metres squared.
| Adult BMI | General classification |
|---|---|
| 18.5–24.9 | Standard reference range |
| 25.0–29.9 | Overweight |
| 30.0–34.9 | Obesity, class I |
| 35.0–39.9 | Obesity, class II |
| 40.0 or higher | Obesity, class III |
However, BMI does not directly measure body fat or distinguish muscle from fat. The relationship between BMI and health risk also differs across populations.
A comprehensive assessment may include waist circumference, blood pressure, glucose and cholesterol tests, sleep-apnea symptoms, medication history and other relevant factors.
What Health Problems Are Associated With Obesity?
Obesity can increase the risk of:
- Type 2 diabetes and cardiovascular disease.
- High blood pressure and abnormal cholesterol.
- Obstructive sleep apnea.
- Metabolic dysfunction-associated steatotic liver disease (MASLD).
- Joint pain and reduced mobility.
- Certain cancers and other chronic conditions.
The purpose of treatment is to improve overall health and well-being, not simply to achieve a particular number on the scale.
How Common Is Obesity? Latest WHO Statistics
The World Health Organization (WHO) updated its obesity fact sheet on October 7, 2026, using estimates for 2024.
According to that report:
- 1.1 billion people worldwide were living with obesity in 2024, approximately one in seven people.
- 940 million adults were living with obesity.
- Approximately 16% of adults worldwide were affected by obesity.
- Adult obesity prevalence has more than doubled since 1990.
These are global population estimates, not measures of treatment success.
The WHO recognizes obesity as a complex chronic disease requiring prevention, appropriate treatment and sustained support.
Source: WHO — Obesity and Overweight, updated October 2026.
What Are the Main Obesity Treatment Options?
Treatment plans may combine several approaches.
| Treatment | Main purpose | Important consideration |
|---|---|---|
| Medical nutrition therapy | Establish a sustainable eating pattern | Requires individualization |
| Physical activity and resistance training | Improve fitness and help preserve muscle | Should match mobility and medical conditions |
| Behavioral treatment | Address eating patterns, sleep, stress and habits | Continued support may improve maintenance |
| Prescription weight-loss medication | Help regulate appetite, satiety or nutrient absorption | Medical supervision and side-effect monitoring required |
| Metabolic and bariatric surgery | Produce substantial weight loss in appropriately selected patients | Requires surgery and lifelong follow-up |
These treatments are not mutually exclusive.
For example, a patient taking medication may also benefit from nutrition counseling, while someone who has undergone bariatric surgery needs long-term dietary support.
1. Lifestyle-Based Obesity Treatment
Lifestyle treatment is an important component of obesity care, whether or not medication or surgery is used.
Medical Nutrition Therapy
A registered dietitian or qualified nutrition professional can help patients develop a realistic eating plan that considers medical conditions, food preferences and everyday routines.
Common strategies include:
- Choosing vegetables, fruits, legumes and other fiber-rich foods.
- Including adequate protein and nutrient-dense foods.
- Reducing frequent intake of sugary drinks and highly energy-dense foods.
- Managing portion sizes without unnecessarily restrictive diets.
- Adapting meals for diabetes, cardiovascular disease or other conditions.
There is no single dietary pattern that is best for everyone.
For additional information, explore Nutrition and Health on Tabeebo.
Physical Activity and Strength Training
Adults are generally encouraged to work toward at least 150 minutes of moderate-intensity aerobic activity each week, together with muscle-strengthening activities on at least two days.
Some people may need a gradual starting program because of joint pain, reduced mobility or other health conditions.
Resistance training is particularly valuable for supporting muscle strength during weight loss.
Behavioral and Psychological Support
Structured behavioral interventions can help patients manage eating triggers, sleep difficulties, stress, planning and treatment adherence.
When eating disorders or significant psychological concerns are present, appropriate specialist assessment is important.
A sustainable treatment plan should be practical and medically appropriate, rather than built around punishment, extreme restriction or unrealistic weight targets.
2. Weight-Loss Medications: What Options Exist?
Prescription medications may be considered when lifestyle-based treatment alone does not provide sufficient health improvement.
In the United States, adults may generally be considered for weight-management medication when they have:
- BMI of 30 or higher, or
- BMI of 27 or higher with a weight-related health condition, such as type 2 diabetes or hypertension.
These are common US prescribing criteria, not universal rules for every country or medication.
| Medication | How it works | Main considerations |
|---|---|---|
| Semaglutide | Activates GLP-1 receptors to help regulate appetite and satiety | Gastrointestinal side effects; suitability and formulation vary |
| Tirzepatide | Activates GIP and GLP-1 receptors | Can produce substantial weight loss; monitoring required |
| Liraglutide | GLP-1 receptor agonist | Usually requires daily injection in weight-management use |
| Orlistat | Reduces absorption of some dietary fat | Oily stools, diarrhea and possible vitamin-related concerns |
| Naltrexone/bupropion | Affects pathways involved in appetite and food reward | Not suitable for certain patients, including those using opioids or with uncontrolled hypertension |
| Phentermine/topiramate | Combines appetite-related mechanisms | Important pregnancy-related and other contraindications |
Metformin is primarily used for diabetes and selected other conditions. Although it may modestly affect body weight, it is not an FDA-approved obesity medication.
Brand names and approved indications vary by country. For example, Wegovy is a semaglutide brand with US weight-management indications, while Ozempic is primarily authorized for type 2 diabetes and certain associated indications. Tirzepatide is marketed under different brands, including Zepbound and Mounjaro, depending on the indication and jurisdiction.
Medication selection must consider the full prescribing information applicable in the treatment country.
3. Semaglutide vs. Tirzepatide: What Does Recent Research Show?
One of the most informative recent studies is SURMOUNT-5, published in The New England Journal of Medicine in May 2025.
The randomized trial included 751 adults with obesity but without type 2 diabetes, comparing specified weekly injectable doses of tirzepatide and semaglutide over 72 weeks.
| Medication | Mean weight reduction at 72 weeks |
|---|---|
| Tirzepatide | 20.2% |
| Semaglutide | 13.7% |
The difference was statistically significant in this study.
For illustration, a 20.2% reduction from a starting weight of 100 kg would be 20.2 kg. However, this is an explanation of the trial percentage, not a prediction of any patient’s outcome.
The study was sponsored by Eli Lilly, and its findings apply to the studied population, doses and treatment conditions.
It does not establish that one medicine is the best option for every patient.
Source: Aronne et al. — Tirzepatide Compared with Semaglutide for Obesity, NEJM 2025.
What Does the WHO Recommend About GLP-1 Medicines?
In December 2025, the WHO published its first global guideline addressing GLP-1-based medicines for obesity.
It issued conditional recommendations supporting long-term use in eligible adults, excluding pregnant women, as part of comprehensive obesity treatment.
The WHO highlighted uncertainties concerning long-term outcomes, affordability, access and maintenance after stopping medication.
Its recommendation reinforces the importance of combining appropriate medication with nutrition, physical activity and professional support.
Source: WHO — Global Guideline on GLP-1 Therapies, December 2025.
4. Risks and Side Effects of Weight-Loss Medications
The safety profile depends on the specific medicine.
GLP-1-based treatments may cause:
- Nausea, vomiting, diarrhea or constipation.
- Abdominal discomfort.
- Dehydration, particularly when gastrointestinal symptoms are severe.
- Gallbladder problems.
- Pancreatitis, which requires urgent assessment if suspected.
Certain US products containing semaglutide or tirzepatide are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
These medicines should not be used for weight loss during pregnancy. Patients planning pregnancy should discuss discontinuation and timing with the prescribing clinician.
Patients should obtain prescription medicines through licensed pharmacies and avoid unverified online injections or products with uncertain ingredients.
Persistent severe abdominal pain, repeated vomiting or signs of dehydration require prompt medical evaluation.
5. Bariatric Surgery: Who May Qualify?
Metabolic and bariatric surgery is an established treatment option for selected patients with obesity.
The 2022 ASMBS/IFSO guidelines recommend surgery for individuals with:
- BMI of 35 or higher, regardless of obesity-related conditions.
- BMI of 30–34.9 in selected patients with metabolic disease or inadequate improvement after appropriate nonsurgical treatment.
Lower BMI thresholds may be relevant for certain Asian populations.
These recommendations are not identical to eligibility or insurance rules in every country.
Main Bariatric Procedures
| Surgery | Main features | Long-term consideration |
|---|---|---|
| Sleeve gastrectomy | Removes a substantial portion of the stomach | Can worsen or contribute to reflux in some patients |
| Roux-en-Y gastric bypass | Creates a small stomach pouch and reroutes part of the intestine | Greater risk of certain nutritional deficiencies and dumping syndrome |
| Other metabolic procedures | Techniques selected for particular medical circumstances | Different nutritional and surgical risks |
Adjustable gastric banding is now less commonly performed in many settings and should not be presented as an equivalent first-line option for every patient.
Risks of bariatric surgery include bleeding, infection, blood clots, leaks, nutritional deficiencies and possible need for further procedures.
Patients typically require long-term vitamin and mineral supplementation and follow-up, according to the procedure and medical assessment.
For surgical indications, preparation and recovery, read the separate Bariatric Surgery Guide on Tabeebo.
Can Obesity Treatment Improve Diabetes and Heart Health?
Even a moderate reduction in body weight can improve certain health markers.
According to the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), losing approximately 5–10% of starting body weight may improve blood glucose, blood pressure and triglycerides.
For some patients, treatment can also improve sleep apnea, joint symptoms and metabolic health.
The benefits depend on the individual’s health conditions and chosen treatment.
Patients with obesity and type 2 diabetes can also explore Diabetes Management on Tabeebo.
Why Does Weight Sometimes Return After Treatment?
Weight regain is common because obesity involves biological adaptations that affect appetite, energy expenditure and satiety.
After stopping some prescription medicines, people may regain part of the weight they lost.
This does not mean a treatment had no value, but it highlights the need for an ongoing plan.
Long-term management may include continued medication when appropriate, nutrition support, physical activity, monitoring of metabolic health and regular medical follow-up.
How Much Does Obesity Treatment Cost?
Costs depend on the country, healthcare system, treatment and duration of care.
A comprehensive plan may include medical consultations, laboratory tests, dietitian appointments, behavioral support, medication and follow-up.
Bariatric surgery includes additional operating-room, anesthesia, hospitalization and postoperative costs.
When comparing providers, ask what the quotation includes and whether additional visits, medicines, nutritional supplements or complications are covered.
Insurance reimbursement and medication availability vary considerably by country.
Frequently Asked Questions
Can obesity be treated without surgery?
Yes. Many patients are treated with nutrition, physical activity, behavioral support and, when appropriate, medication.
Is semaglutide better than tirzepatide?
SURMOUNT-5 reported greater mean weight loss with tirzepatide in its studied population, but individual suitability depends on medical history, contraindications, availability and other factors.
Do weight-loss injections work permanently?
Benefits may persist with continued effective treatment, but weight regain can occur after stopping medication. Long-term management is often necessary.
At what BMI is bariatric surgery recommended?
International guidelines recommend consideration from BMI 35 and, in selected circumstances, at BMI 30–34.9. Individual eligibility depends on medical assessment and local standards.
Can obesity treatment help type 2 diabetes?
Yes. Weight-management treatments may improve blood glucose and other metabolic markers, but diabetes medications must be managed by the treating clinician.
Which specialist treats obesity?
Depending on the patient’s needs, care may involve a physician experienced in obesity medicine, endocrinologist, registered dietitian, behavioral-health professional or bariatric surgeon.
Find Obesity Treatment Specialists on Tabeebo
Effective obesity management starts with an individual medical assessment, a clear explanation of options and a plan for long-term follow-up.
Through Tabeebo, you can explore endocrinologists, compare healthcare providers offering obesity treatment and review available nutrition and surgical services.
For additional practical information, read Comprehensive Guide to Weight Loss: Tips, Treatments and Advice.
Medical and Scientific References
- WHO — Obesity and Overweight, updated October 2026.
- WHO — Guideline on GLP-1 Medicines for Obesity, December 2025.
- NIDDK — Prescription Medications to Treat Overweight and Obesity.
- Aronne et al. — SURMOUNT-5 Randomized Trial, NEJM 2025.
- ASMBS/IFSO — Indications for Metabolic and Bariatric Surgery.
- DailyMed — Current Zepbound Prescribing Information.
- DailyMed — Current Wegovy Prescribing Information.
Medical disclaimer: This article provides general health information and does not replace individualized advice from a qualified healthcare professional. Treatment eligibility, drug approvals and prescribing rules vary by country. Tabeebo is a healthcare directory and does not itself provide obesity treatment.











